Table 1.
Demographics and comorbidities by hospitalization status in pregnant patients with SARS-CoV-2 infection
| Characteristics | All pregnant patients (N=240)a | Not hospitalized for COVID-19 concern (n=216) | Hospitalized for COVID-19 concern (n=24) | P value |
|---|---|---|---|---|
| Demographics | ||||
| Age (y) | 28 (24–34) | 28 (24–33) | 32 (26–35) | .04 |
| Race | .14 | |||
| American Indian or Alaska Native | 10 (4.2) | 8 (3.7) | 2 (8.3) | |
| Asian | 8 (3.3) | 8 (3.7) | 0 (0) | |
| Native Hawaiian or other Pacific Islander | 8 (3.3) | 5 (2.3) | 3 (12.5) | |
| Black or African American | 20 (8.3) | 19 (8.8) | 1 (4.2) | |
| White | 113 (47.1) | 104 (48.2) | 9 (37.5) | |
| Multiracial | 2 (0.8) | 2 (0.9) | 0 (0) | |
| Other | 28 (11.7) | 26 (12.0) | 2 (8.3) | |
| Unknown | 51 (21.3) | 44 (20.4) | 7 (29.2) | |
| Ethnicity | .29 | |||
| Hispanic or Latino | 126 (52.5) | 117 (54.2) | 9 (37.5) | |
| Not Hispanic or Latino | 108 (45.0) | 94 (43.5) | 14 (58.3) | |
| Unknown | 6 (2.5) | 5 (2.3) | 1 (4.2) | |
| Type of insurance at diagnosis | .11 | |||
| Public | 160 (66.7) | 146 (67.6) | 14 (58.3) | |
| Private | 74 (30.8) | 66 (30.6) | 8 (33.3) | |
| Other | 4 (1.7) | 2 (0.9) | 2 (8.3) | |
| Uninsured | 1 (0.4) | 1 (0.5) | 0 (0) | |
| Unknown | 1 (0.4) | 1 (0.5) | 0 (0) | |
| Pregnancy historyb | ||||
| Parity | 1 (1–3) | 1 (1–2) | 1.5 (1–4) | .08 |
| History of preterm birth | 23 (9.6) | 21 (9.8) | 2 (8.3) | .82 |
| Prepregnancy comorbidities or underlying conditions | ||||
| Any comorbidity or underlying condition (excluding obesity)c | 49 (20.4) | 38 (17.6) | 11 (45.8) | .001 |
| Asthma | 20 (8.3) | 15 (6.9) | 5 (20.8) | .02 |
| Type 2 diabetes mellitus | 13 (5.4) | 10 (4.6) | 3 (12.5) | .11 |
| Hypertension | 11 (4.6) | 6 (2.8) | 5 (20.8) | <.001 |
| Cardiovascular disease | 6 (2.5) | 5 (2.3) | 1 (4.2) | .58 |
| Autoimmune disease | 4 (1.7) | 2 (0.9) | 2 (8.3) | <.01 |
| Hypothyroidism | 4 (1.7) | 3 (1.4) | 1 (4.2) | .31 |
| Prepregnancy BMI (kg/m2)d | .02 | |||
| Underweight (<18.5) | 3 (1.3) | 3 (1.5) | 0 (0) | |
| Normal (18.5–24.9) | 57 (25.3) | 55 (26.7) | 2 (10.5) | |
| Overweight (25.0–29.9) | 63 (28.0) | 56 (27.2) | 7 (36.8) | |
| Obese (≥30.0) | 102 (45.3) | 92 (44.7) | 10 (52.6) | |
| Class 3 obesity (BMI of ≥40 kg/m2)d | 17 (7.6) | 13 (6.3) | 4 (21.1) | .02 |
BMI, body mass index; COVID-19, coronavirus disease 2019; IQR, interquartile range; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Lokken et al. COVID-19 disease and mortality in pregnancy. Am J Obstet Gynecol 2021.
Summarized as number (percentage) or median (IQR)
Parity and history of preterm birth missing for 1 participant
Comorbidities assessed for the data collection tool included diabetes mellitus, asthma, reactive airway disease, hypertension, hypothyroidism, cardiovascular disease, autoimmune disease, HIV, immunosuppressive medication use, cirrhosis, hepatitis A history, hepatitis C antibody, previous or current cancer, tuberculosis, prepregnancy kidney disease, chronic obstructive pulmonary disease, seizure disorder, and cerebrovascular disease
Data only available for 225 patients. Prepregnancy weight or weight before 12 weeks’ gestational age was used if prepregnancy weight was not available. For 1 patient, their weight at 14 weeks’ gestation was used to calculate prepregnancy BMI.